Search Results

You are looking at 1 - 2 of 2 items for

  • Author: Bagher Larijani x
Clear All Modify Search
Restricted access

Hanieh-Sadat Ejtahed, Raul Y Tito, Seyed-Davar Siadat, Shirin Hasani-Ranjbar, Zahra Hoseini-Tavassol, Leen Rymenans, Kristin Verbeke, Ahmad-Reza Soroush, Jeroen Raes and Bagher Larijani


The increasing prevalence of obesity over the past few decades constitutes a global health challenge. Pharmacological therapy is recommended to accompany life-style modification for obesity management. Here, we perform a clinical trial to investigate the effects of metformin on anthropometric indices and gut microbiota composition in non-diabetic, treatment-naive obese women with a low-calorie diet (LCD).


Randomized double-blind parallel-group clinical trial


Forty-six obese women were randomly assigned to the metformin (500 mg/tab) or placebo groups using computer-generated random numbers. Subjects in both groups took two tablets per day for 2 months. Anthropometric measurements and collection of blood and fecal samples were done at the baseline and at the end of the trial. Gut microbiota composition was assessed using 16S rRNA amplicon sequencing.


Twenty-four and twenty-two subjects were included in the metformin + LCD and placebo + LCD groups, respectively; at the end of trial, 20 and 16 subjects were analyzed. The metformin + LCD and placebo + LCD caused a 4.5 and 2.6% decrease in BMI from the baseline values, respectively (P < 0.01). Insulin concentration decreased in the metformin + LCD group (P = 0.046). The overall fecal microbiota composition and diversity were unaffected in the metformin + LCD group. However, a significant specific increase in Escherichia/Shigella abundance was observed after metformin + LCD intervention (P = 0.026). Fecal acetate concentration, but not producers, was significantly higher in the placebo + LCD group, adjusted for baseline values and BMI (P = 0.002).


Despite the weight reduction after metformin intake, the overall fecal microbiota composition remained largely unchanged in obese women, with exception of changes in specific proteobacterial groups.

Free access

Mohsen Khosravi-Maharlooei, Ensiyeh Hajizadeh-Saffar, Yaser Tahamtani, Mohsen Basiri, Leila Montazeri, Keynoosh Khalooghi, Mohammad Kazemi Ashtiani, Ali Farrokhi, Nasser Aghdami, Anavasadat Sadr Hashemi Nejad, Mohammad-Bagher Larijani, Nico De Leu, Harry Heimberg, Xunrong Luo and Hossein Baharvand

Over the past decades, tremendous efforts have been made to establish pancreatic islet transplantation as a standard therapy for type 1 diabetes. Recent advances in islet transplantation have resulted in steady improvements in the 5-year insulin independence rates for diabetic patients. Here we review the key challenges encountered in the islet transplantation field which include islet source limitation, sub-optimal engraftment of islets, lack of oxygen and blood supply for transplanted islets, and immune rejection of islets. Additionally, we discuss possible solutions for these challenges.